Graziani Francesca, Lillo Rosa, Panaioli Elena, Spagnoletti Gionata, Pieroni Maurizio, Ferrazzi Paolo, Camporeale Antonia, Verrecchia Elena, Sicignano Ludovico Luca, Manna Raffaele, Crea Filippo
Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
ESC Heart Fail. 2021 Feb;8(1):725-728. doi: 10.1002/ehf2.13101. Epub 2020 Nov 19.
In Fabry cardiomyopathy, left ventricular outflow tract obstruction mimicking hypertrophic cardiomyopathy is a very rare finding, with few cases reported and successfully treated with cardiac surgery. In our population of patients with Fabry disease and severe left ventricular hypertrophy (LVH) at the time of diagnosis, we observed an evolution towards a midventricular obstructive phenotype.
We present a case series of three classically affected Fabry male patients with significant diagnostic delay and severe cardiac involvement (maximal wall thickness >20 mm) at first evaluation. All patients developed midventricular obstructive form over time despite prompt initiation and optimal compliance to enzyme replacement therapy. The extension and distribution of the LVH, involving the papillary muscles, was the main mechanism of obstruction, unlike the asymmetric septal basal hypertrophy and the mitral valve abnormalities commonly seen as substrate of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy.
Fabry cardiomyopathy can evolve over time towards a midventricular obstructive form due to massive LVH in classically affected men with significant diagnostic delay and severe LVH before enzyme replacement therapy initiation. This newly described cardiac phenotype could represent an adverse outcome of the disease.
在法布里心肌病中,模仿肥厚型心肌病的左心室流出道梗阻是一种非常罕见的发现,仅有少数病例报告并通过心脏手术成功治疗。在我们诊断时患有法布里病和严重左心室肥厚(LVH)的患者群体中,我们观察到向心室中部梗阻表型的演变。
我们呈现了一个病例系列,包括三名典型受累的法布里男性患者,首次评估时诊断明显延迟且心脏受累严重(最大壁厚>20mm)。尽管及时开始并最佳依从酶替代治疗,但所有患者随时间推移均发展为心室中部梗阻形式。与肥厚型心肌病中通常被视为左心室流出道梗阻基础的不对称室间隔基底肥厚和二尖瓣异常不同,LVH累及乳头肌的范围和分布是梗阻的主要机制。
由于在酶替代治疗开始前诊断明显延迟且LVH严重的典型受累男性中出现大量LVH,法布里心肌病可随时间演变为心室中部梗阻形式。这种新描述的心脏表型可能代表该疾病的不良结局。